EP4320147A4 - MULTIFUNCTIONAL TCR-BINDING MOLECULES AND THEIR USES - Google Patents

MULTIFUNCTIONAL TCR-BINDING MOLECULES AND THEIR USES

Info

Publication number
EP4320147A4
EP4320147A4 EP22785489.0A EP22785489A EP4320147A4 EP 4320147 A4 EP4320147 A4 EP 4320147A4 EP 22785489 A EP22785489 A EP 22785489A EP 4320147 A4 EP4320147 A4 EP 4320147A4
Authority
EP
European Patent Office
Prior art keywords
tcr
multifunctional
binding molecules
molecules
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22785489.0A
Other languages
German (de)
French (fr)
Other versions
EP4320147A2 (en
Inventor
Andreas Loew
Jonathan Hsu
Madan Katragadda
Gurkan Guntas
Sangeetha Palakurthi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marengo Therapeutics Inc
Original Assignee
Marengo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marengo Therapeutics Inc filed Critical Marengo Therapeutics Inc
Publication of EP4320147A2 publication Critical patent/EP4320147A2/en
Publication of EP4320147A4 publication Critical patent/EP4320147A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22785489.0A 2021-04-08 2022-04-07 MULTIFUNCTIONAL TCR-BINDING MOLECULES AND THEIR USES Pending EP4320147A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163172468P 2021-04-08 2021-04-08
PCT/US2022/023922 WO2022216993A2 (en) 2021-04-08 2022-04-07 Multifuntional molecules binding to tcr and uses thereof

Publications (2)

Publication Number Publication Date
EP4320147A2 EP4320147A2 (en) 2024-02-14
EP4320147A4 true EP4320147A4 (en) 2025-06-18

Family

ID=83546591

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22785489.0A Pending EP4320147A4 (en) 2021-04-08 2022-04-07 MULTIFUNCTIONAL TCR-BINDING MOLECULES AND THEIR USES

Country Status (10)

Country Link
US (1) US20250099579A1 (en)
EP (1) EP4320147A4 (en)
JP (1) JP2024515591A (en)
KR (1) KR20240004462A (en)
CN (1) CN117597359A (en)
AU (1) AU2022255506A1 (en)
BR (1) BR112023020832A2 (en)
CA (1) CA3214757A1 (en)
GB (2) GB2643481A (en)
WO (1) WO2022216993A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7579795B2 (en) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド Antibody molecules that bind to NKp30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
KR20250143365A (en) * 2022-10-12 2025-10-01 마렝고 테라퓨틱스, 인크. Multifunctional molecules binding to TCR and uses thereof
EP4601619A4 (en) * 2022-10-12 2026-08-05 Marengo Therapeutics Inc TCR-binding multifunctional molecules and uses thereof
WO2024226532A2 (en) * 2023-04-24 2024-10-31 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
CN116554356B (en) * 2023-05-16 2024-01-23 武汉大学 Fusion protein of hyper IL-15, sCD4 and Fc and application thereof
WO2025217371A2 (en) * 2024-04-12 2025-10-16 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2025222066A1 (en) * 2024-04-17 2025-10-23 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020172596A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and thereof

Family Cites Families (230)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US861745A (en) 1906-11-21 1907-07-30 Jefferson D Maxwell Hydraulic dredging apparatus.
EP0000151B1 (en) 1977-06-28 1981-05-20 Sandoz Ag 1-substituted aminoindolines, process for their production and pharmaceutical compositions containing them
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド Modifications of or for denatured antibodies
US5731116A (en) 1989-05-17 1998-03-24 Dai Nippon Printing Co., Ltd. Electrostatic information recording medium and electrostatic information recording and reproducing method
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (en) 1988-09-02 1997-08-14 Dyax Corp PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING POINTS
FI903489A7 (en) 1988-11-11 1990-07-10 Medical Res Council Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (en) 1990-07-10 2000-02-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF SPECIFIC UNION COUPLE MEMBERS.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
DE69233697T2 (en) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Process for the development of binding microproteins
PT100379B (en) 1991-04-10 1999-01-29 Scripps Research Inst LIBRARIES OF HETERODYMERIC RECEPTORS USING FAGOMIDEOS
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
PT1024191E (en) 1991-12-02 2008-12-22 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
DE69233408T2 (en) 1991-12-02 2005-09-22 Cambridge Antibody Technology Ltd., Melbourn Production of Antibodies on Phage Surfaces Starting from Antibody Segment Libraries.
JP3980657B2 (en) 1992-06-26 2007-09-26 生化学工業株式会社 Chondroitinase ABC, process for producing the same and pharmaceutical composition
DE69334275D1 (en) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobulins without a light chain
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE69334238D1 (en) 1992-09-25 2008-09-25 Aventis Pharma Sa ADENOVIRUS VECTORS FOR THE TRANSMISSION OF FOREIGN GENES IN CELLS OF THE CENTRAL NERVOUS SYSTEM, ESPECIALLY IN THE BRAIN
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
SE9400088D0 (en) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
FR2727867B1 (en) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa GENE TRANSFER IN MEDULLAR MOTONURONES USING ADENOVIRAL VECTORS
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP3614866B2 (en) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド Artificial antibody polypeptide
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DE69941267D1 (en) 1998-12-10 2009-09-24 Bristol Myers Squibb Co PROTEIN EQUIPMENT FOR ANTIBODY-NACHHAMMER AND OTHER BINDING PROTEINS
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
WO2000060070A1 (en) 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
DE19932688B4 (en) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design of beta-sheet proteins of gamma-II-crystalline antibody-like
HK1043608B (en) 1999-08-17 2007-12-07 Biogen Ma Inc. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
US7105149B1 (en) 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
PT2857516T (en) 2000-04-11 2017-08-28 Genentech Inc Multivalent antibodies and uses therefor
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
JP4303105B2 (en) 2001-06-28 2009-07-29 ドマンティス リミテッド Dual specific ligands and their use
AU2003209272A1 (en) 2002-01-16 2003-09-02 Zyomyx, Inc. Engineered binding proteins
AU2003221256A1 (en) 2002-02-21 2003-09-09 Biogen Idec Ma Inc. Use of bcma as an immunoregulatory agent
CN1678634A (en) 2002-06-28 2005-10-05 多曼蒂斯有限公司 Immunoglobulin single variant antigen-binding region and specific constructs thereof
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
ES2367430T3 (en) 2002-12-23 2011-11-03 Wyeth Llc ANTIBODIES AGAINST PD-1 AND ITS USES.
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP1608730B1 (en) 2003-03-28 2013-11-06 Biogen Idec MA Inc. Truncated baff receptors
JP4889493B2 (en) 2003-05-14 2012-03-07 ドマンティス リミテッド Method for recovering a polypeptide that unfolds reversibly from a polypeptide repertoire
DE10324447A1 (en) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generation of artificial binding proteins based on ubiquitin
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
JP5087274B2 (en) 2003-06-30 2012-12-05 ドマンティス リミテッド Polypeptide
WO2005042009A1 (en) 2003-10-20 2005-05-12 Biogen Idec Ma Inc. Therapeutic regimens for baff antagonists
BRPI0509201A (en) 2004-03-23 2007-08-28 Biogen Idec Inc receptor coupling agents and therapeutic uses of these
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
ME01803B (en) 2004-08-05 2010-12-31 Genentech Inc Humanized anti-cmet antagonists
TR201808537T4 (en) 2004-09-23 2018-07-23 Genentech Inc Cysteine modified antibodies and conjugates.
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
US7999077B2 (en) 2004-09-30 2011-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IRTA2 antibodies and methods of use
EP1846449A4 (en) 2005-01-12 2009-07-08 Medarex Inc Irta-2 antibodies and their uses
JP2008528010A (en) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ Methods for creating variable domain sequences of heavy chain antibodies
US7431380B1 (en) 2005-02-24 2008-10-07 Theodore Allen Buresh Louver kit
KR101374454B1 (en) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 Methods for producing polypeptides by regulating polypeptide association
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (en) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. Human monoclonal antibodies to programmed death ligand 1(pd-l1)
KR101866623B1 (en) 2005-11-28 2018-07-04 젠맵 에이/에스 Recombinant monovalent antibodies and methods for production thereof
DK1999154T3 (en) 2006-03-24 2012-12-03 Merck Patent Gmbh MANUFACTURED HETERODIMERED PROTEIN DOMAINS
AU2007285763B2 (en) 2006-08-18 2011-12-15 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
PT2170959E (en) 2007-06-18 2014-01-07 Merck Sharp & Dohme ANTIBODIES FOR THE PD-1 PROGRAMMED DEATH HUMAN RECEPTOR
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
PT2242773T (en) 2008-02-11 2017-09-15 Cure Tech Ltd Monoclonal antibodies for tumor treatment
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
TW201920257A (en) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
EA201500417A1 (en) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. ANTAGONIST COMPOSITIONS PD-1 AND APPLICATIONS
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
MX356367B (en) 2008-12-09 2018-05-25 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
CN102421801B (en) 2009-03-10 2016-03-16 比奥根Ma公司 anti-BCMA antibody
MA33256B1 (en) 2009-04-01 2012-05-02 Genentech Inc Antibody ,,, fcrh5 and methods of use
PE20120877A1 (en) 2009-04-01 2012-08-06 Genentech Inc ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES
BRPI1014089A2 (en) 2009-04-02 2016-04-19 Roche Glycart Ag multispecific antibodies comprising full length antibodies and single chain fab fragments
PT2417156E (en) 2009-04-07 2015-04-29 Roche Glycart Ag Trivalent, bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
TWI507525B (en) 2009-06-26 2015-11-11 Regeneron Pharma Easy-to-separate bispecific antibody with native immunoglobulin form
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
IT1395574B1 (en) 2009-09-14 2012-10-16 Guala Dispensing Spa DISTRIBUTION DEVICE
EP2504360B1 (en) 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc Simultaneous inhibition of pd-l1/pd-l2
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN103079644B (en) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 Anti-TIM-3 antibody
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
BR112013002167A2 (en) 2010-08-24 2016-05-31 Roche Glycart Ag bispecific antibody, pharmaceutical composition, use, method of treatment of a cancer patient and a patient suffering from inflammation
CN103068846B9 (en) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 Bispecific antibodies comprising disulfide-stabilized Fv fragments
CN103429620B (en) 2010-11-05 2018-03-06 酵活有限公司 Antibody design for stable heterodimerization with mutations in the Fc domain
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
WO2012118622A1 (en) 2011-02-19 2012-09-07 Baylor Research Institute Diagnostic and therapeutic uses for b cell maturation antigen
JP2014511836A (en) 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ, エセ.アー. Heterodimeric immunoglobulin
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
JP6400470B2 (en) 2011-05-16 2018-10-03 ジェネロン(シャンハイ)コーポレイション リミテッド Multispecific Fab fusion proteins and methods of use
WO2013002362A1 (en) 2011-06-30 2013-01-03 中外製薬株式会社 Heterodimerized polypeptide
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. METHOD FOR STRENGTHENING THE EFFECTORAL FUNCTION OF THE ORIGINAL POLYEPEPTIDE, ITS OPTIONS AND THEIR APPLICATIONS
LT2748201T (en) 2011-08-23 2018-02-26 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
ES2767135T3 (en) 2011-10-19 2020-06-16 Novimmune Sa Methods for purifying antibodies
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
BR112014012819B1 (en) 2011-11-28 2022-08-16 Merck Patent Gmbh ANTI-PD-L1 ANTIBODY OR ANTIGEN BINDING FRAGMENT AND COMPOSITION
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
KR101814370B1 (en) 2011-12-27 2018-01-12 재단법인 생물기술개발중심 Light chain-bridged bispecific antibody
MX2014009565A (en) 2012-02-10 2014-11-10 Genentech Inc Single-chain antibodies and other heteromultimers.
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
EP3517548A1 (en) 2012-03-13 2019-07-31 NovImmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
SG10201704846VA (en) 2012-03-14 2017-07-28 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
EP3553089A1 (en) 2012-05-10 2019-10-16 Bioatla, LLC Multi-specific monoclonal antibodies
JP6351572B2 (en) 2012-05-10 2018-07-04 ザイムワークス,インコーポレイテッド Heteromultimeric constructs of immunoglobulin heavy chains with mutations in the Fc domain
MX2014014162A (en) 2012-05-24 2015-02-04 Hoffmann La Roche Multispecific antibodies.
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
CA2871386A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
CN104640561A (en) 2012-07-23 2015-05-20 酵活有限公司 Immunoglobulin constructs comprising selective pairing of light and heavy chains
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
CA2879814A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
EP2904093B1 (en) 2012-10-03 2019-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
MX2015003616A (en) 2012-10-08 2015-06-05 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use.
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
EP2934577A1 (en) 2012-12-19 2015-10-28 Adimab, LLC Multivalent antibody analogs, and methods of their preparation and use
CN105102618B (en) 2012-12-27 2018-04-17 中外制药株式会社 heterodimeric polypeptide
MX387324B (en) 2013-01-10 2025-03-18 Genmab Bv HUMAN IGG1 FC REGION VARIANTS AND THEIR USES.
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
TWI682941B (en) 2013-02-01 2020-01-21 美商再生元醫藥公司 Antibodies comprising chimeric constant domains
JP6636803B2 (en) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Method for selection of antibodies to BCMA
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
HK1218930A1 (en) 2013-02-08 2017-03-17 Abbvie Stemcentrx Llc Novel multispecific constructs
US20160015749A1 (en) 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US10047167B2 (en) 2013-03-15 2018-08-14 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh UNION MOLECULES FOR BCMA AND CD3
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CA2904805A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
CA2913363A1 (en) 2013-05-24 2014-11-27 Zymeworks Inc. Modular protein drug conjugate therapeutic
EP3004174B1 (en) 2013-05-31 2019-04-17 Zymeworks Inc. Heteromultimers with reduced or silenced effector function
TWI725931B (en) 2013-06-24 2021-05-01 美商建南德克公司 Anti-fcrh5 antibodies
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
BR112016006929A2 (en) 2013-10-11 2017-09-19 Hoffmann La Roche ANTIBODY, NUCLEIC ACID, EXPRESSION VECTOR, HOST CELL, METHODS OF PREPARING ANTIBODY, TREATMENT OF PATIENTS AND GENERATION OF AN ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE OF THE ANTIBODY
HUE050159T2 (en) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antibodies and methods of administration
CN113248613B (en) 2014-01-15 2024-08-23 豪夫迈·罗氏有限公司 Fc region variants with modified FCRN binding properties
CN110981957B (en) 2014-01-15 2024-12-24 豪夫迈·罗氏有限公司 Fc region variants with improved protein A binding
CN110903398B (en) 2014-01-15 2023-08-15 豪夫迈·罗氏有限公司 Fc region variants with modified FCRN and retained protein A binding properties
EP3107565A4 (en) 2014-02-21 2017-08-23 Regeneron Pharmaceuticals, Inc. Methods, compositions and kits for cell specific modulation of target antigens
UA117289C2 (en) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг MULTISPECIFIC ANTIBODY
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
BR112016024546A2 (en) 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft antibody or antibody fragment, antibody or isolated antibody fragment, antibody-drug conjugate, nucleic acid molecule, host cell, and pharmaceutical composition
DK3107938T3 (en) 2014-05-28 2022-07-11 Zymeworks Inc MODIFIED, ANTIGEN-BINDING POLYPEPTIDE CONSTRUCTS AND USES THEREOF
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
AU2015279321B2 (en) 2014-06-27 2021-03-04 Innate Pharma, S.A. Multispecific antigen binding proteins
EP3174897B1 (en) 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
PL3177643T3 (en) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
PT3215528T (en) 2014-11-06 2019-10-11 Hoffmann La Roche Fc-region variants with modified fcrn-binding and methods of use
RU2713131C1 (en) 2014-11-06 2020-02-03 Ф. Хоффманн-Ля Рош Аг EMBODIMENTS OF Fc-REGION WITH MODIFIED BINDING PROPERTIES OF FcRn AND PROTEIN A
ES2808853T3 (en) 2014-11-20 2021-03-02 Hoffmann La Roche Common light chains and usage procedures
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
ES2935274T3 (en) 2014-12-05 2023-03-03 Merck Patent Gmbh domain swapping antibody
HRP20210582T1 (en) 2014-12-05 2021-09-03 Memorial Sloan Kettering Cancer Center ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF ADMINISTRATION
SMT201900702T1 (en) 2015-01-08 2020-01-14 Genmab As Agonistic tnf receptor binding agents
WO2016115274A1 (en) 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
PT3247728T (en) 2015-01-20 2020-07-16 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN107922476A (en) 2015-03-13 2018-04-17 诺夫免疫股份有限公司 Method for Purifying Bispecific Antibodies
HUE057285T2 (en) 2015-04-13 2022-04-28 Pfizer Therapeutic antibodies and their uses
CA2980460A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
US10323094B2 (en) 2015-06-16 2019-06-18 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
EP3325512B1 (en) 2015-07-23 2023-09-06 Inhibrx, Inc. Multivalent and multispecific gitr-binding fusion proteins
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
TWI811023B (en) 2015-08-17 2023-08-01 美商健生生物科技公司 Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CA3036564A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
CN110437339B (en) * 2018-05-04 2021-08-13 免疫靶向有限公司 Fusion protein type prodrug with interleukin 15 as active component
WO2020010250A2 (en) * 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020172598A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
SG11202109056TA (en) * 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
WO2021138474A2 (en) * 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US12445327B2 (en) * 2020-02-24 2025-10-14 Lg Electronics Inc. Method and apparatus for transceiving and receiving wireless signal in wireless communication system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020172596A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HSU JONATHAN ET AL: "A T cell receptor [beta] chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity", SCIENCE TRANSLATIONAL MEDICINE(SUPPLEMENTARY MATERIALS), vol. 15, no. 724, 1 November 2023 (2023-11-01), pages eadi0258 - eadi0258, XP093274356, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.adi0258 *
MURER PATRIZIA ET AL: "Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation", NEW BIOTECHNOLOGY, vol. 52, 1 September 2019 (2019-09-01), NL, pages 42 - 53, XP093007294, ISSN: 1871-6784, DOI: 10.1016/j.nbt.2019.04.002 *
See also references of WO2022216993A2 *
VANTOUROUR P ET AL.: "Innate TCR[beta]-chain engagement drives human T cells toward distinct memory-like effector phenotypes with immunotherapeutic potentials", 8 December 2023 (2023-12-08), XP093274402, Retrieved from the Internet <URL:https://www.science.org/doi/full/10.1126/sciadv.adj6174?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org> *

Also Published As

Publication number Publication date
CA3214757A1 (en) 2022-10-13
BR112023020832A2 (en) 2023-12-19
EP4320147A2 (en) 2024-02-14
WO2022216993A3 (en) 2022-11-17
GB2623199A (en) 2024-04-10
GB2643481A (en) 2026-02-18
KR20240004462A (en) 2024-01-11
GB202315700D0 (en) 2023-11-29
JP2024515591A (en) 2024-04-10
CN117597359A (en) 2024-02-23
GB2623199B (en) 2026-05-27
AU2022255506A1 (en) 2023-11-09
WO2022216993A2 (en) 2022-10-13
US20250099579A1 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
EP4453039A4 (en) MULTIFUNCTIONAL MOLECULES THAT BIND TO TCR AND THEIR USES
EP4240773A4 (en) NANOBODIES BINDING TO TROP2 AND THEIR USES
EP4117682A4 (en) MODIFIED NUCLEOTIDES AND THEIR USES
MA43186A (en) ANTIBODIES SPECIFICALLY BINDING TO PD-1 AND THEIR USES
EP3849608A4 (en) NEW ANTI-LILRB4 ANTIBODIES AND THEIR USES
EP4100439A4 (en) NEW ANTI-LILRB2 ANTIBODIES AND THEIR USES
EP3958910A4 (en) ANTI-CD45 ANTIBODY-DRUG CONJUGATES AND USES THEREOF
MA52022A (en) ANTIBODIES THAT BIND TO CD39 AND THEIR USES
MA52785A (en) BINDING MOLECULES DIRECTED AGAINST BCMA AND THEIR USES
MA44072A (en) ANTIBODIES SPECIFICALLY BINDING TO HLA-DR AND THEIR USES
EP4359381A4 (en) CBL-B MODULATORS AND THEIR USES
EP3918323A4 (en) ANTI-GAL3 ANTIBODIES AND USES THEREOF
MA53750A (en) ANTI-BCMA ANTIBODIES, B-SPECIFIC ANTIGEN BINDING MOLECULES WHICH BIND TO BCMA AND CD3 AND THEIR USES
MA43308A (en) APRIL-BOUND ANTIBODY MOLECULES AND THEIR USES
EP4196153A4 (en) RAS NEOANTIGENS AND THEIR USES
EP4204450A4 (en) MULTIFUNCTIONAL MOLECULES BINDING TO CALRETICULIN AND USES THEREOF
EP3487533A4 (en) MULTIMERIC MOLECULES ATTACHING OX40 AND USES THEREOF
EP3908603A4 (en) MUC1* ANTIVARIABLE ANTIBODIES AND THEIR USES
EP4093768A4 (en) CAL-T CONSTRUCTIONS AND THEIR USES
EP4132974A4 (en) ANTI-CD98 ANTIBODIES AND THEIR USES
EP3781202A4 (en) PD-1 BINDING ANTIBODIES AND THEIR USES
EP3515948A4 (en) COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF
EP3962954A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES
EP4126229A4 (en) MTORC1 MODULATORS AND THEIR USES
EP4136119A4 (en) MODIFIED CCR POLYPEPTIDES AND THEIR USES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231013

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40107768

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20250519

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20250513BHEP

Ipc: C07K 16/28 20060101ALI20250513BHEP

Ipc: C07K 14/725 20060101AFI20250513BHEP